West Pharmaceuticals has invested in Nanopass technologies to access its expertise in intradermal drug delivery systems.
The investment enables West Pharma and Nanopass to deliver new products to the market and also provides Nanopass with an opportunity to further enhance clinical development efforts and to introduce its micro-needle based devices for intradermal delivery of vaccines and drugs.
DNA2.0, a pharmaceutical company, has announced to acquire MIGS, a contract research organisation to accelerate its protein pharmaceutical research.
The asset purchase agreement enables DNA2.0 to gain a substantial hold of all of the assets of MIGS, as well as develop an unparalleled antibody production and engineering platform.
Image: The investment enables West Pharma and Nanopass to deliver new products to the market. Photo: courtesy of Eschweiler.